<b>Conclusions:</b> In this real-world AMI cohort, SGLT2 inhibitors were prescribed primarily in relation to established indications for HF, T2DM, and CKD, yet their use remained highly variable in the absence of a dedicated recommendation for AMI. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.